Antonio Alvarez Fernandez
Overview
Explore the profile of Antonio Alvarez Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
8
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Felipe Montiel A, Fernandez A, Amigo M, Traversi L, Clofent Alarcon D, Reyes K, et al.
Eur Respir Rev
. 2024 Oct;
33(174).
PMID: 39477350
The prognosis of people with cystic fibrosis (pwCF) has improved dramatically with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (CFTRm). The ageing of the cystic fibrosis (CF)...
2.
Felipe Montiel A, Fernandez A, Amigo M, Blasi F, Gramegna A, Elborn S, et al.
ERJ Open Res
. 2024 May;
10(3).
PMID: 38746857
Background: Significant progress in the field of cystic fibrosis (CF) has substantially extended the life expectancy of patients with CF (pwCF). Consequently, the population of adult pwCF has outnumbered paediatric...
3.
Felipe Montiel A, Fernandez A, Traversi L, Polverino E
Expert Rev Respir Med
. 2024 Feb;
17(12):1091-1094.
PMID: 38347811
No abstract available.
4.
Hernandez L, Moreno R, Balaguer Cartagena M, Pelaez A, Sole A, Fernandez A, et al.
Arch Bronconeumol
. 2023 Jul;
59(9):556-565.
PMID: 37400317
Introduction: Elexacaftor/tezacaftor/ivacaftor (ETI) was used through the early access programme in Spain from December 2019 in cystic fibrosis (CF) patients with homozygous or heterozygous F508del mutation with advanced lung disease....